by qfrsolutions | Aug 7, 2014 | News
Source: FierceBiotech More than 5 years after The Medicines Company ($MDCO) bagged Targanta and its troubled antibiotic oritavancin for the bargain basement rate of $42 million plus potential bonus payments, the biotech has finally nailed down an elusive FDA approval...
by qfrsolutions | Jul 21, 2014 | News
Source: PALO ALTO, Calif.–(BUSINESS WIRE)– Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that it has entered into an exclusive agreement with Sandoz Inc., a Novartis company, pursuant to which Sandoz will distribute and commercialize...
by qfrsolutions | Jul 18, 2014 | News
Source: With a bid reaching nearly $55 billion and some goodies for the top execs, AbbVie ($ABBV) was finally able to get Ireland-based Shire ($SHPG) to surrender its independence, a portfolio of attention deficit hyperactivity disorder and rare disease drugs, and its...
by qfrsolutions | Jul 17, 2014 | News
Source: Danish dermatology specialist LEO Pharma and Canada’s KLOX Technologies, both privately-held companies, have entered into a worldwide license and joint venture agreement, excluding Canada, to further develop and commercialize KLOX’s BioPhotonic...
by qfrsolutions | Jul 15, 2014 | News
Source: FierceBiotech Innovative technology offers potential to transform eye care and further enhance Alcon’s leadership in contact lenses and intraocular lenses Agreement is a first step for Novartis to evolve technology to manage human diseases and conditions...
